Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.

• Main Authors: Rao, B, van Leeuwen, I.M., Higgins, M., Campbel, J., Thompson, A.M., Lane, D.P., Lain, S.
• Other Authors: MEDICINE
• Format: Article
• Published: 2020
• Subjects: aneugen; antineoplastic agent; aurora kinase; dactinomycin; imidazole derivative; nutlin 3; piperazine derivative; protein serine threonine kinase; tozasertib; aneuploidy; article; cell cycle; cell proliferation; cell protection; cell strain HCT116; dose response; drug antagonism; drug effect; evaluation; gene inactivation; genetics; human; neoplasm; pathology; physiology; tumor cell line; tumor suppressor gene; Aneugens; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cytoprotection; Dactinomycin; Dose-Response Relationship, Drug; Gene Knockout Techniques; Genes, p53; HCT116 Cells; Humans; Imidazoles; Neoplasms; Piperazines; Protein-Serine-Threonine Kinases
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/177792
• Institution: National University of Singapore

10.18632/oncotarget.198